vs
Apyx Medical Corp（APYX）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是Apyx Medical Corp的43.1倍（$826.4M vs $19.2M）。GLOBUS MEDICAL INC净利率更高（17.0% vs -6.8%，领先23.8%）。Apyx Medical Corp同比增速更快（34.7% vs 25.7%）。GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-2.8M）。过去两年Apyx Medical Corp的营收复合增速更高（36.8% vs 16.7%）
Apyx Medical前身是博维医疗，是美国的医疗器械制造商，专注生产电外科产品与能源技术相关医疗设备，公司总部位于佛罗里达州克利尔沃特，在保加利亚设有生产工厂。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
APYX vs GMED — 直观对比
营收规模更大
GMED
是对方的43.1倍
$19.2M
营收增速更快
APYX
高出9.0%
25.7%
净利率更高
GMED
高出23.8%
-6.8%
自由现金流更多
GMED
多$205.2M
$-2.8M
两年增速更快
APYX
近两年复合增速
16.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $19.2M | $826.4M |
| 净利润 | $-1.3M | $140.6M |
| 毛利率 | 62.6% | 68.4% |
| 营业利润率 | 0.1% | 20.5% |
| 净利率 | -6.8% | 17.0% |
| 营收同比 | 34.7% | 25.7% |
| 净利润同比 | 71.9% | 430.4% |
| 每股收益（稀释后） | — | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APYXGMED
| Q4 25 | $19.2M | $826.4M | ||
| Q3 25 | $12.9M | $769.0M | ||
| Q2 25 | $11.4M | $745.3M | ||
| Q1 25 | $9.4M | $598.1M | ||
| Q4 24 | $14.2M | $657.3M | ||
| Q3 24 | $11.5M | $625.7M | ||
| Q2 24 | $12.1M | $629.7M | ||
| Q1 24 | $10.2M | $606.7M |
净利润APYXGMED
| Q4 25 | $-1.3M | $140.6M | ||
| Q3 25 | $-2.0M | $119.0M | ||
| Q2 25 | $-3.8M | $202.8M | ||
| Q1 25 | $-4.2M | $75.5M | ||
| Q4 24 | $-4.6M | $26.5M | ||
| Q3 24 | $-4.7M | $51.8M | ||
| Q2 24 | $-6.6M | $31.8M | ||
| Q1 24 | $-7.6M | $-7.1M |
毛利率APYXGMED
| Q4 25 | 62.6% | 68.4% | ||
| Q3 25 | 64.4% | 67.2% | ||
| Q2 25 | 62.3% | 66.6% | ||
| Q1 25 | 60.1% | 67.3% | ||
| Q4 24 | 63.0% | 59.9% | ||
| Q3 24 | 60.5% | 56.8% | ||
| Q2 24 | 61.7% | 58.7% | ||
| Q1 24 | 58.1% | 60.2% |
营业利润率APYXGMED
| Q4 25 | 0.1% | 20.5% | ||
| Q3 25 | -6.5% | 17.9% | ||
| Q2 25 | -22.6% | 10.2% | ||
| Q1 25 | -32.4% | 16.2% | ||
| Q4 24 | -21.4% | 9.2% | ||
| Q3 24 | -31.6% | 7.7% | ||
| Q2 24 | -45.7% | 7.9% | ||
| Q1 24 | -64.6% | 1.3% |
净利率APYXGMED
| Q4 25 | -6.8% | 17.0% | ||
| Q3 25 | -15.4% | 15.5% | ||
| Q2 25 | -33.2% | 27.2% | ||
| Q1 25 | -44.0% | 12.6% | ||
| Q4 24 | -32.5% | 4.0% | ||
| Q3 24 | -40.9% | 8.3% | ||
| Q2 24 | -54.0% | 5.0% | ||
| Q1 24 | -74.0% | -1.2% |
每股收益（稀释后）APYXGMED
| Q4 25 | — | $1.01 | ||
| Q3 25 | — | $0.88 | ||
| Q2 25 | — | $1.49 | ||
| Q1 25 | — | $0.54 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | — | $0.38 | ||
| Q2 24 | $-0.19 | $0.23 | ||
| Q1 24 | $-0.22 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.7M | $557.2M |
| 总债务越低越好 | $37.5M | — |
| 股东权益账面价值 | $14.5M | $4.6B |
| 总资产 | $66.8M | $5.3B |
| 负债/权益比越低杠杆越低 | 2.58× | — |
8季度趋势，按日历期对齐
现金及短期投资APYXGMED
| Q4 25 | $31.7M | $557.2M | ||
| Q3 25 | $25.1M | $18.8M | ||
| Q2 25 | $29.3M | — | ||
| Q1 25 | $31.0M | — | ||
| Q4 24 | $31.7M | $890.1M | ||
| Q3 24 | $28.0M | $71.9M | ||
| Q2 24 | $32.7M | $82.5M | ||
| Q1 24 | $37.3M | $80.4M |
总债务APYXGMED
| Q4 25 | $37.5M | — | ||
| Q3 25 | $37.5M | — | ||
| Q2 25 | $37.5M | — | ||
| Q1 25 | $37.5M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $37.5M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益APYXGMED
| Q4 25 | $14.5M | $4.6B | ||
| Q3 25 | $5.8M | $4.4B | ||
| Q2 25 | $7.3M | $4.3B | ||
| Q1 25 | $10.5M | $4.1B | ||
| Q4 24 | $14.2M | $4.2B | ||
| Q3 24 | $11.0M | $4.1B | ||
| Q2 24 | $14.7M | $4.0B | ||
| Q1 24 | $20.3M | $3.9B |
总资产APYXGMED
| Q4 25 | $66.8M | $5.3B | ||
| Q3 25 | $57.4M | $5.1B | ||
| Q2 25 | $58.2M | $5.0B | ||
| Q1 25 | $60.2M | $4.7B | ||
| Q4 24 | $64.8M | $5.3B | ||
| Q3 24 | $60.7M | $5.1B | ||
| Q2 24 | $65.4M | $5.0B | ||
| Q1 24 | $70.7M | $4.9B |
负债/权益比APYXGMED
| Q4 25 | 2.58× | — | ||
| Q3 25 | 6.41× | — | ||
| Q2 25 | 5.17× | — | ||
| Q1 25 | 3.57× | — | ||
| Q4 24 | 2.64× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.5M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | $-2.8M | $202.4M |
| 自由现金流率自由现金流/营收 | -14.6% | 24.5% |
| 资本支出强度资本支出/营收 | 1.4% | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.77× |
| 过去12个月自由现金流最近4个季度 | $-9.1M | $588.8M |
8季度趋势，按日历期对齐
经营现金流APYXGMED
| Q4 25 | $-2.5M | $248.6M | ||
| Q3 25 | $-3.5M | $249.7M | ||
| Q2 25 | $-1.2M | $77.9M | ||
| Q1 25 | $-702.0K | $177.3M | ||
| Q4 24 | $-2.9M | $210.3M | ||
| Q3 24 | $-4.4M | $203.7M | ||
| Q2 24 | $-4.3M | $54.3M | ||
| Q1 24 | $-6.3M | $52.4M |
自由现金流APYXGMED
| Q4 25 | $-2.8M | $202.4M | ||
| Q3 25 | $-4.1M | $213.9M | ||
| Q2 25 | $-1.5M | $31.3M | ||
| Q1 25 | $-757.0K | $141.2M | ||
| Q4 24 | $-3.2M | $193.2M | ||
| Q3 24 | $-4.6M | $161.7M | ||
| Q2 24 | $-4.6M | $26.5M | ||
| Q1 24 | $-6.4M | $23.8M |
自由现金流率APYXGMED
| Q4 25 | -14.6% | 24.5% | ||
| Q3 25 | -31.5% | 27.8% | ||
| Q2 25 | -13.2% | 4.2% | ||
| Q1 25 | -8.0% | 23.6% | ||
| Q4 24 | -22.4% | 29.4% | ||
| Q3 24 | -40.0% | 25.8% | ||
| Q2 24 | -38.0% | 4.2% | ||
| Q1 24 | -62.2% | 3.9% |
资本支出强度APYXGMED
| Q4 25 | 1.4% | 5.6% | ||
| Q3 25 | 4.0% | 4.7% | ||
| Q2 25 | 2.3% | 6.2% | ||
| Q1 25 | 0.6% | 6.0% | ||
| Q4 24 | 1.7% | 2.6% | ||
| Q3 24 | 1.3% | 6.7% | ||
| Q2 24 | 2.4% | 4.4% | ||
| Q1 24 | 0.3% | 4.7% |
现金转化率APYXGMED
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | — | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APYX
暂无分部数据
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
